Opioid and price fixing legal liabilities mount for generic companies

Four generics companies could face about $14.7 billion in potential penalties related to legal actions, including lawsuits alleging mis-marketing of opioid pills as well as accusations that the companies engaged in price fixing, according to one Wall Street analyst.